Trends in waking salivary alpha-amylase levels following healing lucid dreams

Introduction

Salivary alpha-amylase (sAA) is considered a marker of autonomic nervous system activity in stress research, and atypical waking sAA responses have been reported for traumatized individuals. Lucid dreams, characterized by a dreamer's awareness of their dream state while remaining asleep, have shown promising preliminary evidence of their potential to enhance mental health. This study's objective was to evaluate sAA in relation to healing lucid dreams.

Methods

Participants experiencing PTSD symptoms attended a six-day workshop delivered via live video designed to teach techniques for transforming trauma through dreamwork and dream lucidity. Participants (n = 20) collected saliva samples each morning, immediately upon awakening (Time 1) and 30 min afterward (Time 2). sAA levels were determined by enzymatic assay, and the waking sAA slope was calculated as the difference of Time 2 minus Time 1. Participants completed dream reports each morning, with a dream classified as a 'healing lucid dream' when they reported attaining lucidity and remembered their intention to manifest a healing experience within the dreamscape.

Results

Of eight participants experiencing healing lucid dreams, four were able to provide usable saliva samples. Statistical tests on these four participants were not significant because of low power. However, nonsignificant positive associations were observed between experiencing more healing lucid dreams and increased waking sAA slope.

Conclusion

The results did not reveal a consistent effect of healing lucid dreams on waking sAA slope. Identifying meaningful patterns in this relationship will require larger samples and more stringent control over saliva collection procedures in future studies.

Evaluating brain spectral and connectivity differences between silent mind-wandering and trance states

Trance is an altered state of consciousness characterized by alterations in cognition. In general, trance states induce mental silence (i.e., cognitive thought reduction), and mental silence can induce trance states. Conversely, mind-wandering is the mind's propensity to stray its attention away from the task at hand and toward content irrelevant to the current moment, and its main component is inner speech. Building on the previous literature on mental silence and trance states and incorporating inverse source reconstruction advances, the study's objectives were to evaluate differences between trance and mind-wandering states using: (1) electroencephalography (EEG) power spectra at the electrode level, (2) power spectra at the area level (source reconstructed signal), and (3) EEG functional connectivity between these areas (i.e., how they interact). The relationship between subjective trance depths ratings and whole-brain connectivity during trance was also evaluated. Spectral analyses revealed increased delta and theta power in the frontal region and increased gamma in the centro-parietal region during mind-wandering, whereas trance showed increased beta and gamma power in the frontal region. Power spectra at the area level and pairwise comparisons of the connectivity between these areas demonstrated no significant difference between the two states. However, subjective trance depth ratings were inversely correlated with whole-brain connectivity in all frequency bands (i.e., deeper trance is associated with less large-scale connectivity). Trance allows one to enter mentally silent states and explore their neurophenomenological processes. Limitations and future directions are discussed.

Amygdala Hyperactivity at Rest in Paranoid Individuals With Schizophrenia

OBJECTIVE

The amygdala's role in threat perception suggests that increased activation of this region may be related to paranoid ideation. However, investigations of amygdala function in paranoid individuals with schizophrenia, compared with both healthy individuals and nonparanoid individuals with schizophrenia, have consistently reported reduced task-related activation. The reliance of blood-oxygen-level-dependent functional MRI on a contrast between events and baseline, and the inability to quantitatively measure this baseline, may account for these counterintuitive findings. The present study tested for differences in baseline levels of amygdala activity in paranoid and nonparanoid individuals with schizophrenia using arterial spin labeling perfusion MRI.

METHOD

Resting cerebral blood flow (CBF) and task-related activation of the amygdala were measured in 25 healthy individuals, 16 individuals with schizophrenia who were actively paranoid at the time of scanning, and 16 individuals with schizophrenia who were not paranoid.

RESULTS

Analysis of relative CBF values extracted from the amygdala bilaterally revealed significantly increased activity in the left amygdala in paranoid patient volunteers compared with healthy comparison subjects and nonparanoid patient volunteers. Increased CBF was also evident in the right amygdala but did not reach the level of statistical significance. Paranoid volunteers also showed significantly decreased task-related activation of the amygdala compared with the two other groups.

CONCLUSIONS

These findings suggest that amygdala hyperactivation may underlie paranoia in schizophrenia. Additionally, the reported differences between paranoid and nonparanoid patient volunteers emphasize the importance of considering symptom-based subgroups and baseline levels of activity in future investigations of neural activation in schizophrenia.

Ghrelin as a target for gastrointestinal motility disorders

The therapeutic potential of ghrelin and synthetic ghrelin receptor (GRLN-R) agonists for the treatment of gastrointestinal (GI) motility disorders is based on their ability to stimulate coordinated patterns of propulsive GI motility. This review focuses on the latest findings that support the therapeutic potential of GRLN-R agonists for the treatment of GI motility disorders. The review highlights the preclinical and clinical prokinetic effects of ghrelin and a series of novel ghrelin mimetics to exert prokinetic effects on the GI tract. We build upon a series of excellent reviews to critically discuss the evidence that supports the potential of GRLN-R agonists to normalize GI motility in patients with GI hypomotility disorders such as gastroparesis, post-operative ileus (POI), idiopathic chronic constipation and functional bowel disorders.